Prospective evaluation of lipid management following acute coronary syndrome in non-Western countries
| datacite.rights | http://purl.org/coar/access_right/c_abf2 | eng |
| dc.contributor.author | Navar, Ann Marie | |
| dc.contributor.author | Matskeplishvili, Simon T. | |
| dc.contributor.author | Urina-Triana, Miguel | |
| dc.contributor.author | Arafah, Mohammed | |
| dc.contributor.author | Chen, Jaw-Wen | |
| dc.contributor.author | Sukonthasarn, Apichard | |
| dc.contributor.author | Corp dit Genti, Valérie | |
| dc.contributor.author | Daclin, Véronique | |
| dc.contributor.author | Peterson, Eric D. | |
| dc.date.accessioned | 2021-06-09T20:26:11Z | |
| dc.date.available | 2021-06-09T20:26:11Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | Background: Half the global burden of cardiovascular disease (CVD) is concentrated in the Asia-Pacific (APAC) region. Hypothesis: Suboptimal control of low-density lipoprotein cholesterol (LDL-C) may play a large role in the burden of CVD in APAC and non-Western countries. Methods: The Acute Coronary Syndrome Management (ACOSYM) registry is a multinational, multicenter, prospective observational registry designed to evaluate LDL-C control in patients within 6 months after hospitalization following an acute coronary syndrome (ACS) event across nine countries. Results: Overall, 1581 patients were enrolled, of whom 1567 patients met the eligibility criteria; 80.3% of the eligible patients were men, 46.1% had ST-elevation myocardial infarction, and 39.5% had non-ST-elevation myocardial infarction. Most (1245; 79.5%) patients were discharged on a high-intensity statin. During the followup, only 992 (63.3%) patients had at least one LDL-C measurement; of these, 52.9% had persistently elevated LDL-C (>70 mg/dl). The patients not discharged on a highdose statin were more likely (OR 3.2; 95% CI 2.1–4.8) to have an LDL-C above the 70 mg/dl LDL-C target compared with those who were discharged on a high-dose statin. Conclusion: Our real-world registry found that a third or more of post-ACS patients did not have a repeat LDL-C follow-up measurement. In those with an LDL-C followup measurement, more than half (52.9%) were not achieving a <70 mg/dl LDL-C goal, despite a greater uptake of high-intensity statin therapy than has been observed in recent evidence. This demonstrates the opportunity to improve post-ACS lipid management in global community practice. | eng |
| dc.format.mimetype | spa | |
| dc.identifier.doi | DOI: 10.1002/clc.23623 | |
| dc.identifier.issn | 19328737 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/7897 | |
| dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1002/clc.23623 | |
| dc.language.iso | eng | eng |
| dc.publisher | Wiley | eng |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | eng |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.source | Clinical Cardiology | eng |
| dc.source | Vol.1 N° 8, (2021) | |
| dc.subject | Acute coronary syndrome | eng |
| dc.subject | Iipid management | eng |
| dc.subject | Low-density lipoprotein cholesterol | eng |
| dc.subject | Non- Western countries | eng |
| dc.subject | Statin therapy | eng |
| dc.title | Prospective evaluation of lipid management following acute coronary syndrome in non-Western countries | eng |
| dc.type.driver | info:eu-repo/semantics/article | eng |
| dc.type.spa | Artículo científico | spa |
| dcterms.references | Kaptoge S, Pennells L, De Bacquer D, et al. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health. 2019;7(10):e1332-e1345. https://doi.org/10.1016/S2214-109X(19)30318-3. | eng |
| dcterms.references | Lawes CMM, Rodgers A, Bennett DA, et al. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens. 2003;21(4): 707-716. | eng |
| dcterms.references | Poh KK, Ambegaonkar B, Baxter CA, et al. Low-density lipoprotein cholesterol target attainment in patients with stable or acute coronary heart disease in the Asia-Pacific region: results from the Dyslipidemia International Study II. Eur J Prev Cardiol. 2018;25(18):1950-1963. https://doi.org/10.11622/smedj.2019021. | eng |
| dcterms.references | Sillars A, Sattar N. Management of lipid abnormalities in patients with diabetes. Curr Cardiol Rep. 2019;21(11):147. | eng |
| dcterms.references | Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24): 3168-3209. | eng |
| dcterms.references | Singh M, McEvoy JW, Khan SU, et al. Comparison of transatlantic approaches to lipid management: the AHA/ACC/Multisociety guidelines vs the ESC/EAS guidelines. Mayo Clin Proc. 2020;95(5):998- 1014. https://doi.org/10.1016/j.mayocp.2020.01.011 | eng |
| dcterms.references | Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32 (14):1769-1818. https://doi.org/10.1093/eurheartj/ehr158. | eng |
| dcterms.references | Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017; 376(18):1713-1722. | eng |
| dcterms.references | Murphy SA, Pedersen TR, Gaciong ZA, et al. Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease. JAMA Cardiol. 2019;4(7):613-619. https:// jamanetwork.com/journals/jamacardiology/fullarticle/2733138. | eng |
| dcterms.references | Danchin N, Almahmeed W, Al-Rasadi K, et al. Achievement of lowdensity lipoprotein cholesterol goals in 18 countries outside Western Europe: the International ChoLesterol management Practice Study (ICLPS). Eur J Prev Cardiol. 2018;25(10):1087-1094. https://doi.org/ 10.1177/2047487318777079. | eng |
| dcterms.references | Wang Y, Yan BP, Tomlinson B, Lee VWY. Is lipid goal one-size-fits-all: a review of evidence for recommended low-density lipoprotein treatment targets in Asian patients. Eur J Prev Cardiol. 2019;26(14):1496- 1506. https://doi.org/10.1177/2047487319843077. | eng |
| dcterms.references | Nakamura M, Ako J, Arai H, et al. Investigation into lipid management in acute coronary syndrome patients from the EXPLORE-J study. J Atheroscler Thromb. 2019;26(6):559-572. https://doi.org/10.5551/jat.45583. | eng |
| dcterms.references | Li Y-H, Ueng K-C, Jeng J-S, et al. 2017 Taiwan lipid guidelines for high risk patients. J Formos Med Assoc. 2017;116(4):217-248. https:// doi.org/10.1016/j.jfma.2016.11.013. | eng |
| dcterms.references | Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596- e646. https://doi.org/10.1161/CIR.0000000000000678. | eng |
| dcterms.references | Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. Hoboken, NJ: John Wiley & Sons, Inc; 2000. http://doi.org/10.1002/ 0471722146. | eng |
| oaire.version | info:eu-repo/semantics/publishedVersion | eng |